List of press releases (including news briefing topics)

Sunday for Monday story (embargo: 00.01 hrs Monday 21 September)

New blood tests promise simple, cost-effective diagnosis of gastrointestinal cancers.

J. Louwagie (abstract no: 12 LBA) & U. Stein (abstract no: 13 LBA)

Session: Gastro-intestinal malignancies – colorectal cancer 1, 11-13.15 hrs CEST (Hall 2)

Sunday press conference at 16.00 hrs CEST). NB: Stories have different embargoes (see below)

Surgical removal of primary tumour improves survival in metastatic breast cancer patients. Embargoed to 11.00 hrs, Monday.

Dr Jetske Ruiterkamp (abstract no: 5005)

Session: Breast Cancer 1 – advanced disease, Monday 11.00-13.00 hrs CEST (Hall 1)

Can aspirin prevent cancer in people with an inherited predisposition to colon cancer? International clinical trial has the answer. Embargoed to 11.00 hrs, Monday

Dr John Burn (abstract no: 6000)

Session: Gastro-intestinal malignancies, colorectal cancer session, Monday 11.00 hrs CEST (Hall 2)

New European Academy of Cancer Sciences will help shape future oncology policy. Embargoed to 13.00 hrs, Monday.

Prof Alexander Eggermont

Session: Presidential 1, The unified approach: meeting the cancer challenges in the next decade, Monday 13.15-16.0 hrs CEST (Hall 1)

Monday

One general press release in German for the local German media

Tuesday press conference at 11.15 hrs. NB: Stories have different embargoes (see below)

Largest and most comprehensive study to date investigates links between prostate cancer hormone therapy and heart disease. Embargoed to 11.15 hrs Tues.

Ms Mieke Van Hemelrijck (abstract no: 0272)

Session: Presidential, Tuesday 12.15 hrs CEST (Hall 1)

Expert calls for new cancer research priorities and outlines strategy to cope with growing burden of cases. Embargoed to 09.00 hrs Tues.

Prof Richard Sullivan

Session: European Partnership for Action Against Cancer, Tuesday 09.00 hrs CEST (Hall 15.3)

Potentially practice-changing results of phase III trial combining targeted heat therapy with chemotherapy in locally advanced soft tissue sarcoma. Embargoed to 11.15 hrs Tues.

Prof Rolf Issels (abstract no: 1 LBA)

Session: Presidential II, Tuesday 12.15-14.15 hrs CEST (Hall 1)

Other press releases, all embargoed to 00.01 hrs on Tuesday 22 September

Meta-analysis clarifying the impact of adding cetuximab to various chemotherapy combinations in advanced non-small cell lung cancer.

Prof Jean-Louis Pujol (abstract no: 9009)

Session: Lung Cancer II, Tuesday 09.00 hrs CEST (Hall 15.2)

Findings of the first study of teen experiences during the process of obtaining a cancer diagnosis.

Ms Susie Pearce (abstract no: 4170)

Session: Experiences of Care proffered papers, Tuesday 09.00 hrs CEST (Hall 10)

Largest study to date investigates the effect of whole-brain radiotherapy in patients with limited spread of primary cancer to the brain.

Dr Riccardo Soffietti (abstract no: 8704)

Session: Central Nervous System proffered papers session, Tuesday 09.00 hrs CEST (Hall 7)

Keep taking the medicine: study of adjuvant endocrine treatment for breast cancer reveals the cost of patient non-compliance

Prof Cornelis van de Velde (abstract no: 2 BA)

Session: Presidential session, Tuesday 12.30-14.30 hrs CEST (Hall 1)

Switching early breast cancer patients to exemestane improves long-term survival

Charles Coombes (abstract 5010)

Session: Breast cancer II – Early disease, Tuesday 09.00-11.00 hrs CEST (Hall 1)

Wednesday press conference at 11.15 hrs. NB: Stories have different embargoes (see below)

Significant advances made in treatment of malignant melanoma: two trials show improvements in overall survival and rapid shrinking of tumours. Embargoed to 11.15 hrs on Wednesday.

Steven O’Day (abstract no: 23 LBA) & Paul Chapman (abstract no: 6LBA)

Sessions: O’Day: Melanoma and skin cancer session, Wednesday, 14.45-17.00 hrs CEST (Hall 7); Chapman: Presidential session IV, Thursday, 9.30-11.15 hrs CEST (Hall 1)

Could HPV vaccination and screening eradicate cervical cancer? Embargoed to 11.15 hrs CEST on Thursday 24 September.

Prof Jack Cuzick

Session: Oncopolicy: Drug and lifestyle mediated prevention initiatives in Europe. Thursday 11.15-12.15 hrs CEST (Hall 3)

New figures on the numbers of new cancers in Europe caused by excess body fat. Embargoed to 11.15 hrs on Thursday 24 September.

Dr Andrew Renehan (abstract no: 327)

Session: Oncopolicy: Drug and lifestyle mediated prevention initiatives in Europe. Thursday 11.15-12.15 hrs CEST (Hall 3)

Other Wednesday press releases. NB: different embargoes, see below

New research on ultrasound shows it can predict tumour burden and survival in melanoma patients, sparing unnecessary surgery. Embargoed to 09.45 hrs on Wednesday

Dr Christiane Voit (abstract no: 9303)

Session: Melanoma, Wednesday 09.00-10.30 hrs CEST (Hall 7)

New results from SOLTI randomised trial on use of sorafenib in combination with chemotherapy in advanced breast cancer. Embargoed to 12.30 hrs on Wednesday

Prof José Baselga (abstract no: 3 LBA)

Session: Presidential III, Wednesday 12.30-14.30 hrs CEST (Hall 1)

Innovative test for new cancer drugs will lead to quicker validation and safer and more efficient clinical trials. Embargoed to 13.00 hrs CEST on Wednesday

Dr Ilona Schonn (abstract no: 1013)

Session: Basic Science/Translational Research poster discussion, Wednesday 17.00 – 18.00 hrs CEST (Hall 14.2)

Thursday press releases. NB: check embargoes below

Pancreatic cancer: researchers find drug that reverses resistance to chemotherapy. Embargoed to 09.30 hrs CEST on Thursday.

Dr Davide Melisi (abstract no: 1002)

Session: Basic science/translational research, Thursday 09.00 hrs CEST (Hall 14.2)

Genetic identification of patients who are hypersensitive to radiotherapy helps improve treatment and avoid side-effects. Embargoed to 10.45 hrs CEST on Thursday

Prof Dirk de Ruysscher (abstract no: 2007)

Session: Radiotherapy and Radiobiology, Thursday 10.45 hrs CEST (Hall 15.3)